BioCentury
ARTICLE | Financial News

Labopharm proposes follow-on

April 19, 2006 1:38 AM UTC

Labopharm (TSX:DDS) proposed to sell 10 million shares in a follow-on underwritten by Merrill Lynch; Banc of America Securities; Canaccord; Leerink; Orion Securities; Dundee; and Westwind Partners. If sold at DDS's close of C$8.42 on Monday, DDS would raise C$84.2 million (US$73.1 million). The shares will be sold from a previously filed shelf registration. DDS said that the offering will be made mostly to U.S. investors and that it expects that following the offering, the company's shares will be listed on NASDAQ. ...